Compare OGN & EFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGN | EFC |
|---|---|---|
| Founded | 1923 | 2007 |
| Country | United States | United States |
| Employees | N/A | 400 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2020 | N/A |
| Metric | OGN | EFC |
|---|---|---|
| Price | $7.22 | $12.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $11.75 | ★ $14.54 |
| AVG Volume (30 Days) | ★ 4.5M | 2.0M |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | 1.10% | ★ 12.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $6,216,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.65 | N/A |
| P/E Ratio | $10.11 | ★ $9.50 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.18 | $11.12 |
| 52 Week High | $15.88 | $14.12 |
| Indicator | OGN | EFC |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 36.49 |
| Support Level | $6.85 | $12.36 |
| Resistance Level | $7.74 | $14.00 |
| Average True Range (ATR) | 0.36 | 0.24 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 40.52 | 37.85 |
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.